Cycling peptides: what on/off periods are for

A cell's response to persistent stimulation of a receptor diminishing over time. The mechanisms vary — receptors can be internalised and removed from the surface, or the signalling machinery downstream of them can be dialled back — but the observable result is the same: the same amount produces less effect.

A break allows that to recover. Whether it applies to a given compound depends on whether it stimulates a receptor persistently and strongly enough to trigger the adaptation, which is a property of the compound rather than a general rule.

Hormonal systems are largely self-regulating: the body senses the level of a hormone and adjusts its own production accordingly. Supplying something from outside a regulated axis can therefore suppress the body's own output of it.

That matters where the compound sits within such an axis. Whether suppression reverses, and how quickly, depends on the specific axis, and it is not something a general article can tell you — but it is the reason breaks are taken more seriously for some compound classes than others.

It is a precaution rather than a mechanism, and it is worth being honest about the difference. For a compound with no long-term human safety data — which describes most of what people cycle — a break is not treating a biological process. It is reducing total exposure to something whose long-term profile is unknown.

That is a defensible reason. It is just not the same kind of reason as desensitisation, and presenting it as though it were gives it a false precision.

No — not on your own initiative. The approved GLP-1 receptor agonists used for ongoing metabolic conditions are designed for continuous use, and interrupting them is a clinical decision with clinical consequences rather than a protocol optimisation.

Stopping and restarting such a medication without your prescriber is not cycling; it is non-adherence, and with a long-half-life compound it also means repeating the climb to steady state every time you resume.

The desensitisation rationale fits them poorly as usually stated. If a compound clears completely between administrations, receptors are already getting regular unstimulated intervals — the break is built into the dosing pattern.

That does not mean no break is warranted, only that the argument for one has to come from somewhere else: cumulative exposure, feedback effects, or a documented adaptation specific to that compound.

Not automatically. A break has costs as well as benefits — for anything being used to manage a condition, the interruption is itself a risk, and repeatedly restarting a long-acting compound means repeatedly traversing the unsteady part of the curve.

The useful question is not 'should I cycle' but 'what is this specific break for'. If you cannot answer that, the schedule is a ritual rather than a plan.

Biologically, once the compound has cleared. For a short-acting compound the distinction is trivial — hours against a break measured in weeks. For a long-acting one it is substantial.

A compound with a week-long half-life is still meaningfully present a month after the last dose, which means the first several weeks of a nominal break are not a break in any biological sense. A four-week 'off period' on such a compound may contain almost no time at genuinely low levels.

It changes the starting point rather than the duration. If you dosed long enough to reach steady state, clearance begins from the plateau rather than from a single dose, so there is more to eliminate — but the five-half-lives span is the same.

The practical consequence is that a break planned in calendar weeks and a break measured in exposure are different quantities, and only one of them is what you meant.

Clearance is the floor. Whatever the break was meant to accomplish — resensitising a receptor, letting a suppressed axis recover — has its own timeline, and pharmacokinetics does not predict it.

So a break shorter than clearance definitely has not worked, and a break longer than clearance may or may not have. That asymmetry is the useful thing the calculation gives you.

Because 'about six weeks' a year later is worthless for comparison. Cycles are only informative relative to each other, and that requires the boundaries to be facts rather than recollections.

It also matters for anything time-dependent: how long a gap actually was, whether an effect appeared before or after a change, how long into a cycle something started.

Because attribution is impossible without it. Training, sleep, diet, other compounds, season, stress and life circumstances all move at the same time, and a record showing only the compound implicitly credits it with everything.

This is the single biggest difference between a log that produces insight and one that just produces data. It is also the part people skip, because it feels like it is not about the protocol.

Because it is where you find out whether anything persisted. An effect that disappears the week you stop is telling you something different from one that holds for two months, and neither is visible if the log goes quiet the moment dosing does.

Almost nobody records the off period, which means almost nobody has the comparison that would make their on periods interpretable.